tbuckley/cabot-search huggingface dataset:
Bevacizumab plus etoposide among recurrent malignant glioma patients: Phase II study final results
Authors: D. Reardon, A. Desjardins, J. J. Vredenburgh, S. Gururangan, K. B. Peters, J. A. Norfleet
Journal: Journal of Clinical Oncology (2009)

2046 Background: Significant therapeutic benefit has been observed among recurrent malignant glioma (MG) patients treated with bevacizumab (BV), a neutralizing monoclonal antibody to vascular endothelial growth factor (VEGF) with or without chemotherapy. In this study, we evaluate the efficacy of BV plus etoposide (E), a topoisomerase inhibitor, among recurrent MG patients. Methods: Recurrent patients with no more than three prior episodes of recurrence are eligible, while those with prior BV treatment or prior intracranial hemorrhage are excluded. The primary outcome measure is 6 month progression-free survival (6-PFS). BV is dosed at 10 mg/kg intravenously every other week. Etoposide is orally administered daily (50 mg/m2) for days 1–21 of each 28-day cycle. Results: Fifty-nine patients (GBM, n = 27; grade 3 MG, n = 32) with a median of 2 prior progressions have enrolled. With a median follow-up of 45 weeks, median overall survival (OS) for GBM and grade 3 MG patients were 46 and 47 weeks, while the 6-PFS is 44% and 40.6%, respectively. The most common toxicities were neutropenia (41%), fatigue (22%), and infection (20%) and were grade 2 in most cases. One patient developed grade 1 intracranial hemorrhage and 1 patient had a grade 4 GI perforation. Conclusions: Combination of bevacizumab and etoposide is well tolerated in recurrent MG patients and is associated with encouraging anti-tumor benefit. Accrual is complete and an update of further treatment and follow-up will be presented. No significant financial relationships to disclose.
Myocardial Infarction Associates With a Distinct Pericoronary Adipose Tissue Radiomic Phenotype
Authors: Andrew Lin, Márton Kolossváry, Jeremy Yuvaraj, Sebastien Cadet, Priscilla A McElhinney, Cathy Jiang, Nitesh Nerlekar, Stephen J Nicholls, Piotr J Slomka, Pál Maurovich-Horvat, Dennis T L Wong, Damini Dey
Journal: JACC. Cardiovascular imaging (2020)
Neoadjuvant exemestane for 24 weeks in postmenopausal women with hormone receptor positive stage II or IIIA breast cancer (JFMC34–0601)
Authors: N. Sato, N. Masuda, S. Saji, H. Takei, Y. Yamamoto, H. Sasano, M. Toi
Journal: Journal of Clinical Oncology (2009)

591 Background: Exemestane (EXE) is a steroidal aromatase inhibitor and has shown efficacy for not only metastatic breast cancer but also for primary breast cancer situation. Recently it is reported that preoperative treatment with EXE for 24weeks (wks) is more effective than 8 or 16wks. This study aimed to evaluate 24wks treatment of EXE in the neoadjuvant setting for hormone receptor positive, stage II/IIIA, postmenopausal breast cancer. Methods: Stage II/IIIA pts were eligible with confirmed invasive breast cancer and ER/PgR status using needle biopsy. Primary endpoints were ORR and Safety. EXE 25mg/day was administered, and if pts were evaluated CR, PR, SD at 16wks, 8wks treatment was added. Additionally rates of breast conserving surgery (BCS), nodal status, biomarker changes and the relationship between response and survival are being investigated. Results: Between March 2006 and January 2008, 116 pts were enrolled (stage IIA:77%, IIB:20%, III:3%). All pts were ER +, and 80 (69%) were PgR+, and 29 (27.1%) were HER-2+, respectively. At 24 wks, 109pts were evaluable. OR rate was 53% (58/109) and SD rate was 39% (43/109) by investigator's evaluation. Two pts withdrew due to the adverse events. At diagnosis 14 pts would have required mastectomy and after treatment only 5 pts underwent mastectomy. Central pathological review exhibited that biomarker changes during the treatment correlated with tumor response. Conclusions: EXE has shown attractive response for hormone receptor positive breast cancer in neoadjuvant setting. Especially 24wks treatment seems effective with sufficient safety and tolerability. Additional investigations are conducted to explore predictive biomarkers for response and survival. [Table: see text]
Outcome prediction by the 70-gene profile in the context of the National Comprehensive Cancer Network (NCCN) guidelines
Authors: F. A. de Snoo, M. Knauer, R. A. Bender, L. Stork-Sloots, E. J. Rutgers, A. M. Glas, S. C. Linn, L. J. Van 't Veer
Journal: Journal of Clinical Oncology (2009)

535 Background: According to the NCCN consensus guidelines molecular profiling for breast cancer prognosis may be used in patients with ER-positive, Her2-negative and LN-negative disease. Current proposed NCCN clinical risk assessment suggests adjuvant treatment for the majority of these patients. The 70-gene profile (MammaPrint) is validated as an independent prognostic indicator for patients with lymph node-negative and positive disease. Prognosis prediction by MammaPrint may be more suitable to indicate who needs adjuvant chemotherapy in addition to endocrine therapy. Methods: 566 tumor samples of women with ER-positive, Her2-negative and LN- negative breast cancer from 5 previously reported studies were analyzed and classified by MammaPrint as good or poor prognosis. 10-year breast cancer-specific survival (BCSS) was analyzed according to MammaPrint and the NCCN guidelines. Results: Median follow-up was 3.5 years (range 0.1–21.1). 380 of 566 patients (67%) were classified as good and 186 (33%) as poor prognosis by MammaPrint. Using the NCCN guidelines, 7% were classified as low and 93% as high risk respectively. 349 patients (62%) received no adjuvant treatment, 17% received hormonal treatment only, 2% chemotherapy only and 20% both respectively. At 10 years, BCSS was 91% vs. 67% for the good and poor prognosis groups (HR 4.0 [95%CI 2.0–7.9], p&lt;0.001) whith MammaPrint risk assessment. If the NCCN guidelines were used, BCSS was 86% vs. 83% for the low and high risk groups (HR 1.11 [0.3–4.6), p=0.888). In multivariate analysis, adjusted for known prognostic factors and adjuvant therapy, only MammaPrint and histological grade were independent predictors for 10-year-BCSS with HRs of 2.8 (1.3–6.1, p=0.008) and 1.9 (1.1–3.1, p=0.015), respectively. Conclusions: MammaPrint is a strong and independent prognostic indicator in ER-positive, Her2-negative, LN-negative breast cancer and is discordant in 62% of cases when compared with the NCCN guidelines. MammaPrint identifies approximately 66% of NCCN high risk patients as having a good prognosis. Integration of MammaPrint into clinical risk assessment and adjuvant treatment selection can provide a large benefit for management of patients with endocrine-responsive early breast cancer. [Table: see text]
Mailings, Phone Calls Increase Post-MI Cardiac Rehabilitation
Authors: Anita Slomski
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The impact of length of hospitalization following surgical resection of stage I non-small cell lung cancer on long-term survival
Authors: A. Kilic, M. J. Schuchert, J. R. Landreneau, J. P. Landreneau, A. Oostdyk, D. O. Wilson, J. D. Luketich, R. J. Landreneau
Journal: Journal of Clinical Oncology (2009)

7584 Background: The aim of this study was to evaluate the impact of length of hospital stay (LOS) following surgical resection of stage I non-small cell lung cancer (NSCLC) on long-term survival. Methods: We reviewed the records of patients undergoing surgical resection for stage I NSCLC at our institution between 1990–2003. Patients not surviving hospitalization related to their surgery were excluded from analysis. Multivariate analysis was utilized to evaluate the impact of age, gender, tumor histology, tumor stage, LOS, and type of operation (lobar or sublobar) on long-term (&gt;5 year) survival. As a secondary analysis, Kaplan-Meier survival curves of patients stratified according to LOS were compared using the log-rank test. Two-tailed p-values less than 0.05 were considered statistically significant. Results: A total of 730 patients underwent lobectomy (n=518) or sublobar resection during the study time period. There were 18 (2.5%) operative or in-hospital mortalities. Median LOS was 6 (range 1–81) and 7 (range 1–46) days in the lobar and sublobar cohorts, respectively. Patients with a longer hospital stay (≥14 days) had significantly worse 5- and 10-year overall survival rates as compared to those with a shorter hospitalization (lobectomy: 5-year- 60.3% vs 33.8%; 10-year-27.3% vs 8.4%; p&lt;0.001; sublobar: 5-year-44.3% vs 11.7%; 10-year-9.9% vs 0%; p=0.006). There were 171 patients with extended clinical follow-up who had survived at least 5 years (mean follow-up = 88.1 ± 2.0 months). Multivariate analysis demonstrated that LOS predicted long-term survival independent of patient age, gender, tumor histology, tumor stage, and type of operation (p=0.013). Conclusions: LOS following surgical resection of stage I NSCLC is an independent predictor of long-term survival. These survival differences related to hospital stay may be related to underlying medical co-morbidities important to the decision making regarding therapy of patients with otherwise resectable stage I lung cancer. Prospective assessment of medical co-morbidities may be an important initiative for future treatment planning of early stage lung cancer patients. No significant financial relationships to disclose.
Ultra-processed food intake in association with BMI change and risk of overweight and obesity: A prospective analysis of the French NutriNet-Santé cohort
Authors: Marie Beslay, Bernard Srour, Caroline Méjean, Benjamin Allès, Thibault Fiolet, Charlotte Debras, Eloi Chazelas, Mélanie Deschasaux, Méyomo Gaelle Wendeu-Foyet, Serge Hercberg, Pilar Galan, Carlos A. Monteiro, Valérie Deschamps, Giovanna Calixto Andrade, Emmanuelle Kesse-Guyot, Chantal Julia, Mathilde Touvier
Journal: PLoS Medicine (2020)

Background Ultra-processed food (UPF) consumption has increased drastically worldwide and already represents 50%–60% of total daily energy intake in several high-income countries. In the meantime, the prevalence of overweight and obesity has risen continuously during the last century. The objective of this study was to investigate the associations between UPF consumption and the risk of overweight and obesity, as well as change in body mass index (BMI), in a large French cohort. Methods and findings A total of 110,260 adult participants (≥18 years old, mean baseline age = 43.1 [SD 14.6] years; 78.2% women) from the French prospective population-based NutriNet-Santé cohort (2009–2019) were included. Dietary intakes were collected at baseline using repeated and validated 24-hour dietary records linked to a food composition database that included >3,500 different food items, each categorized according to their degree of processing by the NOVA classification. Associations between the proportion of UPF in the diet and BMI change during follow-up were assessed using linear mixed models. Associations with risk of overweight and obesity were assessed using Cox proportional hazard models. After adjusting for age, sex, educational level, marital status, physical activity, smoking status, alcohol intake, number of 24-hour dietary records, and energy intake, we observed a positive association between UPF intake and gain in BMI (β Time × UPF = 0.02 for an absolute increment of 10 in the percentage of UPF in the diet, P < 0.001). UPF intake was associated with a higher risk of overweight (n = 7,063 overweight participants; hazard ratio (HR) for an absolute increase of 10% of UPFs in the diet = 1.11, 95% CI: 1.08–1.14; P < 0.001) and obesity (n = 3,066 incident obese participants; HR10% = 1.09 (1.05–1.13); P < 0.001). These results remained statistically significant after adjustment for the nutritional quality of the diet and energy intake. Study limitations include possible selection bias, potential residual confounding due to the observational design, and a possible item misclassification according to the level of processing. Nonetheless, robustness was tested and verified using a large panel of sensitivity analyses. Conclusions In this large observational prospective study, higher consumption of UPF was associated with gain in BMI and higher risks of overweight and obesity. Public health authorities in several countries recently started to recommend privileging unprocessed/minimally processed foods and limiting UPF consumption. Trial registration ClinicalTrials.gov NCT03335644 (https://clinicaltrials.gov/ct2/show/NCT03335644)
A phase II trial of adding cetuximab to cisplatin and gemcitabine as first-line therapy in advanced non-small cell lung cancer (NSCLC)
Authors: F. Barata, B. Parente, E. Teixeira, A. Costa, A. Fernandes, F. L. Pimentel, L. Carvalho
Journal: Journal of Clinical Oncology (2009)

e19043 Background: Phase II and III studies have demonstrated that the EGFR-antibody, cetuximab (Erbitux), improves efficacy parameters when added to a platinum-based chemotherapy in the 1st-line treatment of patients with advanced NSCLC. This study assessed the efficacy and tolerability of cetuximab in combination with cisplatin and gemcitabine in this setting. Methods: Patients in this multicenter, single-arm, phase II Portuguese study received cetuximab (400 mg/m 2 initial dose then 250 mg/m 2 weekly) in combination with cisplatin (40 mg/m 2 ) and gemcitabine (1,200 mg/m 2 ) for 6 cycles (21 days). Main eligibility criteria included metastatic NSCLC of any histological subtype, ECOG PS 0/1, and measurable disease. Patients with brain metastases were excluded. The primary endpoint was the overall response rate (ORR) during treatment, according to RECIST criteria. Secondary endpoints included time to progression (TTP), overall survival, and adverse events. Statistical analyses were performed for the intention to treat (ITT) and per protocol populations. ORRs and the corresponding 95% confidence intervals (CIs) were estimated and Kaplan-Meier curves were computed for TTP. Results: A total of 48 patients were enrolled between December 2006 and March 2008. Seventy five percent of the patients were men and the median age was 62.5 years (range 34–75). Median TTP was 5.0 months (95% CI 3.9–6.1 months). Best ORR were 35.4% (95% CI 22.2–50.5%) and 38.1% (95% CI 23.6–54.4%) for the ITT and PP populations, respectively. No differences in response rates were observed when EGFR status (as determined by FISH and immunohistochemistry) was taken into consideration. Ninety-six grade III/V adverse events were reported; the most common were neutropenia and thrombocytopenia (36 and 18 events, respectively). Conclusions: Adding cetuximab to cisplatin and gemcitabine demonstrated high efficacy (ORR and TTP) with acceptable toxicities in a nonselected population of patients in 1st-line treatment of NSCLC. No significant financial relationships to disclose.
Artificial Intelligence to Support Independent Assessment of Screening Mammograms—The Time Has Come
Authors: Constance Dobbins Lehman
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Wearable Sensor-Based Sign Language Recognition: A Comprehensive Review
Authors: Karly Kudrinko, Emile Flavin, Xiaodan Zhu, Qingguo Li
Journal: IEEE Reviews in Biomedical Engineering (2020)

Sign language is used as a primary form of communication by many people who are Deaf, deafened, hard of hearing, and non-verbal. Communication barriers exist for members of these populations during daily interactions with those who are unable to understand or use sign language. Advancements in technology and machine learning techniques have led to the development of innovative approaches for gesture recognition. This literature review focuses on analyzing studies that use wearable sensor-based systems to classify sign language gestures. A review of 72 studies from 1991 to 2019 was performed to identify trends, best practices, and common challenges. Attributes including sign language variation, sensor configuration, classification method, study design, and performance metrics were analyzed and compared. Results from this literature review could aid in the development of user-centred and robust wearable sensor-based systems for sign language recognition.
HP0031 A national survey of parents and grandparents with rheumatoid arthritis, ankylosing spondylitis and back pain: preliminary findings
Authors: MI Grant, CC Wright, LA Cullen, NE Foster, JH Barlow
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Research interest in parents and grandparents with musculoskeletal conditions in relation to their experiences of childcare is growing. <h3>Objectives</h3> To survey parents and grandparents with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and back pain (BP), in the United Kingdom. <h3>Methods</h3> 448 participants (280 BP, 106 AS, 62 RA) responded to a cross-sectional postal survey. Age range was 23 to 88 years, range of duration of symptoms was &lt;1–58 years and the sample was made up of 280 parents and 168 grandparents. Participants were recruited via voluntary organisations and Rheumatology Clinics. The majority of participants with RA and BP were female. Data were analysed using SPSS and content analysis. <h3>Results</h3> The most prevalent problems, with childcare, were keeping up with children (e.g. energy) (87%), playing games (74%), feeling guilty about not being able to carry out routine childcare activities (74%). Other problems included, dressing, talking to children about arthritis, lifting and holding children, social activities, walking children to school, preparing meals, bathing, disciplining children. Participants with RA had the highest prevalence of difficulties overall. Grandparents reported a lower prevalence of problems than parents. Pain (100%), fatigue (90%) and stiffness (96%) were felt to cause difficulties with childcare. Guilt (40%), anxiety (37%) and depression (34%) were also felt to be contributory factors. The majority of participants with AS and BP had not received any advice on childcare but a third of those with RA had. Advice was given by occupational therapists (17%), general practitioners (12%), physiotherapists (7%) and rheumatologists (3%). <h3>Conclusions</h3> Parents and grandparents with RA, AS and BP experience a wide range of problems with childcare (both physical and psychosocial) and do not appear to be receiving appropriate advice. This may indicate a gap in service provision for this group.
Phase I study of TP300 in patients (pts) with advanced solid tumors
Authors: D. A. Anthoney, I. MacPherson, C. Twelves, D. Crawford, C. Siller, S. Nemat, M. Abe, M. Miwa, J. Evans
Journal: Journal of Clinical Oncology (2009)

2563 Background: TP300 (CH4556300) is a synthetic camptothecin analogue and potent topoisomerase I inhibitor designed to have superior efficacy, tolerability and pharmacokinetic (PK) characteristics compared to current inhibitors. Intravenous (i/v) TP300 undergoes rapid chemical conversion to the active compound CH0793076, then enzymatic conversion to an active metabolite, CH0793011. The objectives of this study were to determine the dose-limiting toxicities (DLTs), maximum-tolerated dose (MTD) and PK profiles of TP300; antitumor activity and pharmacodynamics (PD) were also evaluated. Methods: Eligible pts with refractory, advanced solid tumors who had adequate PS, hematologic, renal, and hepatic function were recruited into this open-label, modified- Fibonacci dose escalation (“3 + 3” pts/dose level, with expansion at the MTD) study. TP300 was given as a 1-hour i/v infusion 3-weekly; the starting dose was 1 mg/m 2 . The MTD was defined as the dose level below that where &gt; 2 of 3–6 pts experienced DLT. PK profiles of TP300, CH0793076 and CH0793011 were analysed; DNA strand breaks in peripheral blood mononuclear cells (PBMCs) were measured with the comet assay as a PD marker. Results: 32 pts (m=20; f=12), median age 58 (range 31–72), received TP300 at doses of 1, 2, 4, 8, 12, then 10mg/m 2 . The MTD was 10mg/m 2 ; DLTs seen at 12mg/m 2 (2/4 pts) and 10mg/m 2 (3/12 pts) included anaemia, thrombocytopenia and febrile neutropenia. Other grade 3/4 toxicities included lethargy, chills and lower back pain. Diarrhoea was uncommon. Seven pts, all previously treated with irinotecan, had disease stabilisation for 1.5–5 months. CH0793076 PK (AUC and C max ) were linear from 1 to 10mg/m 2 . There was a strong PD relationship between CH0793076 AUC and fall in neutrophils, the threshold AUC for DLT neutropenia being 5 hr.umol/L. DNA strand breaks were detected consistently in PBMCs on completion of TP300 infusion . Conclusions: The Phase II starting dose will be 8mg/m 2 because hematologic toxicity was seen in cycle 1 at the MTD. As the AUC of CH0793076 at MTD is substantially greater than that of SN38 in pts treated with irinotecan, and CH0793076 is almost equipotent to SN38 pre-clinically, a PK advantage for TP300 is confirmed. Further investigation is warranted. [Table: see text]